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Abstract
Amyloid precursor protein (APP) mutations associated with familial Alzheimer’s disease (AD) usually lead to increases in
amyloid b-protein (Ab) levels or aggregation. Here, we identified a novel APP mutation, located within the Ab sequence
(AbD7H), in a Taiwanese family with early onset AD and explored the pathogenicity of this mutation. Cellular and
biochemical analysis reveal that this mutation increased Ab production, Ab42/40 ratio and prolonged Ab42 oligomer state
with higher neurotoxicity. Because the D7H mutant Ab has an additional metal ion-coordinating residue, histidine, we
speculate that this mutation may promote susceptibility of Ab to ion. When co-incubated with Zn
2+ or Cu
2+,A bD7H
aggregated into low molecular weight oligomers. Together, the D7H mutation could contribute to AD pathology through a
‘‘double punch’’ effect on elevating both Ab production and oligomerization. Although the pathogenic nature of this
mutation needs further confirmation, our findings suggest that the Ab N-terminal region potentially modulates APP
processing and Ab aggregation, and further provides a genetic indication of the importance of Zn
2+ and Cu
2+ in the
etiology of AD.
Citation: Chen W-T, Hong C-J, Lin Y-T, Chang W-H, Huang H-T, et al. (2012) Amyloid-Beta (Ab) D7H Mutation Increases Oligomeric Ab42 and Alters Properties of
Ab-Zinc/Copper Assemblies. PLoS ONE 7(4): e35807. doi:10.1371/journal.pone.0035807
Editor: Ashley I. Bush, Mental Health Research Institute of Victoria, Australia
Received January 30, 2012; Accepted March 22, 2012; Published April 30, 2012
Copyright:  2012 Chen et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by Taiwan National Health Research Institutes NHRI-EX100-9816NC, Taiwan National Science Council grants NSC97-2320-B-
010-027-MY3 and NSC100-2320-B-010-020, Taiwan Ministry of Education Aim for Top University Grant (for IHC); Taipei Veterans General Hospital grant V97C1-098
(for CJH); Molecular Medicine Program, Taiwan International Graduate Program, Institute of Biomedical Sciences, Academia Sinica (for WTC); and Genomics
Research Center, Academia Sinica, National Science Council grant 98-2320-B-001-020-MY3 (for YRC). The funders had no role in study design, data collection and
analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: hjcheng@ym.edu.tw (IHC); yrchen@gate.sinica.edu.tw (YRC)
Introduction
Alzheimer’s disease (AD) is characterized neuropathologically
by progressive brain deposition of the amyloid b peptide (Ab),
which is generated by proteolytic cleavage of amyloid precursor
protein (APP) by b- and c-secretases (Fig. 1A). The two most
common Ab variants have 40 (Ab40) or 42 (Ab42) amino acids.
The abnormal aggregation and accumulation of neurotoxic Ab
have been proposed as the primary driving force for AD in the
amyloid hypothesis [1].
Ab aggregation undergoes multiple pathways with a variety of
intermediates/oligomers formation. The current notion is that low
molecular weight (LMW) assemblies such as soluble oligomers and
protofibrils, but not fibril, are the primary toxic structures of Ab
[2,3]. However, due to the highly dynamic nature of Ab
assemblies and the technical limitation, biochemical features of
toxic Ab aggregates remain unclear [4].
Mutations in the APP gene lead to the early onset familial AD.
Most APP mutations are concentrated either around or within the
Ab domain. APP mutations at the secretase cleavage sites
accelerate the production of Ab, particularly the highly pathogenic
Ab42 [5,6,7,8,9]. Mutations clustered within the 21
st–23
rd residues
of Ab involve enhancing Ab aggregation, delaying Ab elimination
or increasing Ab production [9,10,11,12,13]. Mutations located at
Ab N-terminus, including the English (H6R) and Tottori (D7N)
mutations, have been shown to enhance fibril formation without
altering Ab production [14]. Several potential therapeutic
strategies aimed at reducing Ab production, inhibiting Ab
aggregation, and speeding Ab removal are being developed [15].
Metal ions, especially Zn
2+ and Cu
2+, have been shown to
abnormally accumulate in the amyloid plaques of patients with
AD [16]. The interplay of metal-Ab interaction has been
strengthened recently [17]. Metal ions with redox activity, such
as Cu
2+ and Fe
3+, induce free radicals through the formation of
Ab-ion complex [18]. Zn
2+ and Cu
2+ are known to bind the
histidine residues at Ab N-terminus [19,20]. The metal chelation
therapy is now a potential treatment for AD and undergoing
clinical phase IIb trial [21,22]. However, disruption of ion
homeostasis in the central nervous system by the use of metal
chelator may further deplete the essential metal ions and cause
negative impact on the disease progress [23]. Therefore, to specify
the features of the Ab-ion complex could help to improve the
pharmacological design.
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e35807Here, we report a novel intra-Ab mutation (D7H) in a
Taiwanese family with early onset AD. Because the number of
patients is limited, we explored the pathogenicity of this mutation
with experimental approaches. we propose this mutation is
probable pathogenic because the D7H mutation resulted in
increased levels total Ab, in a higher Ab42/40 ratio and in the
formation of Ab40 fibrils while prolonged Ab42 oligomers state
with higher toxicity. Furthermore, we speculated that the
appearance of one more histidine at the 7
th residue of mutant
Ab may enhance susceptibility to the effect of Zn
2+ or Cu
2+. Our
study reveals that this mutation increased the binding of Zn
2+ and
Cu
2+ and promoted the formation of ion-induced Ab oligomers
with altered morphology. Together, our clinical and experimental
results suggest a pathogenic role of the D7H mutation in familial
AD. We also provide a ‘‘genetic hint’’ for the studies in the metal
as etiology in AD.
Results
Clinical description and genetic analysis
We identified a 53 year-old female AD patient who had
multiple family members affected with memory impairment before
age 65 (Fig. S1A). The index patient had been showing progressive
memory impairment, slurred speech, persecutory delusions, self-
talking and inability to dress herself since age 51. She was restless
and asked the same questions repeatedly during the clinical
examinations. The scores of the mini mental status examination
and the Wechsler Adult Intelligence Scale were 13 and 62,
respectively. The computed tomography (CT) scans revealed
diffuse prominent cerebral fissures, cisterns and sulci. The Tc-
99 m HMPAO single photon emission computed tomography
(SPECT) scans showed hypoperfusion in the bilateral parietal and
left temporal cortices (Fig. 1B). Diffuse background slow waves (6–
7 Hz) were noted by electroencephalography. The results of blood
biochemistry tests for liver function, renal function, thyroid
function, anemia and syphilis were all within normal limits
(Fig. S1B). Diagnosis of probable AD was made according to the
NINCDS–ADRDA criteria. Mutation analysis was done by
directly sequencing PCR-amplified coding exons of PSEN1,
PSEN2 and APP. Sequencing revealed a GRC nucleotide
substitution in the APP gene, resulting in an aspartate to histidine
mutation at 7
th position of Ab (D678H using APP770 numbering
or D7H using Ab numbering, Fig. 1C). This mutation has never
Figure 1. A novel mutation leads to an aspartate to histidine substitution at the N-terminus of Ab. (A) The upper part of the diagram
presents the Ab42 sequence with the location of the D7H mutation (red). As shown in the lower part of the diagram, processing of APP occurs via
two pathways. Nonamyloidogenic processing of APP by a ´-secretase produces the C83 and sAPPa fragments; amyloidogenic processing of APP by a ˆ-
secretase produces the C99 and sAPPb fragments. Ab is generated through subsequent cleavage of C99 by c-secretase. (B) SPECT images of the index
patient indicate hypoperfusion in the bilateral parietal cortices and the left temporal cortex. (C) Direct sequencing of APP exon 16 PCR products
derived from the patient and from healthy controls revealed a GAC-to-CAC nucleotide substitution in Ab region of the patient’s APP gene (in 678
th
amino acid using APP770 numbering or in 7
th amino acid using Ab numbering).
doi:10.1371/journal.pone.0035807.g001
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and 100 Chinese AD patients.
Due to the limited number of patients, we tried to determine the
pathogenicity of this mutation by functional analysis. Both cells
expressing human APP and synthetic Ab peptides were used to
explore the levels of Ab production, Ab42/40 ratio and Ab
aggregation process.
The D7H mutation on APP enhances amyloidogenic
cleavage and increases the Ab42/40 ratio
In the non-amyloidogenic pathway, cleavage of APP within the
Aa ˆ region by a-secretase generates a secreted N-terminal fragment
a (sAPPa) and an 83 amino acid C-terminal fragment (C83) and,
thus, precludes Aa ˆ formation. In the amyloidogenic pathway,
cleavage of APP by b-secretase generates a secreted N-terminal
fragment b (sAPPb) and a 99 amino acid C-terminal fragment
(C99) (Fig. 1A) [24]. To elucidate whether the D7H mutation
shifts the balance between these two pathways, we transiently
transfected human embryonic kidney (HEK293) cells with either
human wild type (wt) or D7H mutant APP cDNA. The
transfection efficiency of both wt and D7H mutant APP are both
,20% (Fig. S2A) and protein expression levels for both wt and
D7H mutant APP were similar (Fig. S2B). In addition, there is no
significant difference in mature/immature APP ratio (Fig. S2C).
The levels of full length APP, the a-secretase cleavage product
C83, and the b-secretase cleavage products C99 and sAPPb were
measured by the Western blot. In cells expressing wt APP, the C83
fragment (,10 kDa) was the predominant species detected. In
cells expressing D7H mutant APP, the C99 fragment (,12 kDa)
was the predominant species detected (Fig. 2A). Densitometric
analysis revealed that the ratio of C99/C83 in cells expressing
D7H mutant APP was 10.3 fold higher than in cells expressing wt
APP (Fig. 2A). Both cells had no significant difference on the level
of b9-cleavage product C89 (,11 kDa). Besides, the level of sAPPb
was significant higher in the conditioned media of cells expressing
D7H mutant APP than that of cells expressing wt APP (Fig. 2B).
Thus, the D7H mutation may shift APP processing from the non-
amyloidogenic to the amyloidogenic cleavage pathway.
The higher C99/C83 ratio may be due to either increased C99
production by b-secretase or to delayed C99 removal by c-
secretase. To distinguish between these two possibilities, we
inhibited c-secretase activity by adding 1 mM L-685,458 to the
media for 24 h. The ratio of C99/C83 in cells expressing D7H
mutant APP was 5.8 fold higher than in cells expressing wt APP
when treated with the inhibitor (Fig. 2C) but was lower than in
cells not treated with inhibitor (10.3 fold). Therefore, both the
production and cleavage of C99 were altered by the D7H
mutation.
We next examined whether the D7H mutation alters the
extracellular and intracellular Ab levels or the Ab42/40 ratio.
HEK293 cells and conditioned media were both collected at 48 h
after APP transfection. Ab levels were measured by enzyme-linked
immunosorbent assay (ELISA) and normalized to total APP level.
The conditioned media of D7H mutant APP transfected culture
had 1.5 fold higher extracellular Ab40 level and 2.4 fold higher
Ab42 level compared to that of the wt APP transfected culture
(Fig. 2D, E). Among all variants of Ab,A b42 is especially prone to
misfolding and aggregating into toxic assemblies [7,8]. We found
that D7H mutant APP transfected culture had a significantly
higher ratio of extracellular Ab42/40 than the wt APP transfected
culture (Fig. 2F). The accumulation of intracellular Ab may also
contribute to the pathogenesis of AD. However, we did not find
significant differences in intracellular Ab levels or in the
intracellular Ab42/40 ratio between wt APP and D7H mutant
APP expressing cells (Fig. S3).
The D7H mutation switches the Ab aggregation process
To investigate the effect of the D7H mutation on Ab
aggregation, we monitored the kinetics of fibril formation, the
size distribution and the morphology of Abwt and AbD7H
assemblies by the thioflavin T (ThT) assay, Western blot, and
transmission electron microscopy (TEM). Synthetic Ab peptides
were dissolved in HFIP-DMSO for the Western blot, toxicity and
TEM experiments and in guanidine hydrochloride (GdnHCl) for
the ThT assay because GdnHCl-denatured Ab allows us to better
distinguish the kinetics of the early stages of aggregation.
The D7H mutation promotes Ab40 fibril formation. In
the ThT analysis of fibrillization kinetics, the lag time of the
initiation of fibril formation for Ab40D7H (,28 h) was longer than
that for Ab40wt (,18 h). However, in the saturation phase, the
ThT fluorescence intensity of Ab40D7H was ,1.5 fold higher than
that of Ab40wt (Fig. 3A). In order to analyze the size distribution of
Ab assemblies by Western blot, we used the photo-induced cross-
linking of unmodified protein (PICUP) approach to ‘‘freeze’’ the
Ab assemblies at indicated time points [25]. At the initial time
point, both Ab40wt and Ab40D7H were predominantly present as
low molecular weight (LMW) assemblies (Fig. 3C). After 96 h of
incubation, more Ab40D7H than Ab40wt aggregated into high
molecular weight (HMW) assemblies. Here, we defined the Ab
assemblies that can be separated by 15% Tricine-PAGEs as LMW
(usually below 78 kDa) while the larger Ab assemblies retaining in
stacking gel as HMW. Using TEM, we observed more fibrillar
structures in the Ab40D7H assemblies and more oligomeric or
protofibrillar structures in the Ab40wt assemblies after 312 h of
incubation (Fig. 4). All of these experiments indicate that the D7H
mutation slightly delays Ab nucleation and promotes the
formation of Ab40 HMW assemblies and fibrils.
The D7H mutation promotes Ab42 LMW assembly
formation. Next, we studied the effect of the D7H mutation
on Ab42 aggregation using the same approaches as described
above for Ab40. Unexpectedly, the D7H mutation did not
promote the formation of Ab42 fibrils but rather prolonged the
duration of Ab42 oligomers.
In the ThT analysis of fibrillization kinetics, the lag time of the
initiation of fibril formation for Ab42D7H (,58 h) was longer than
that for Ab42wt (,18 h). In the saturation phase, the ThT
fluorescence intensity of Ab42D7H was ,1.35 fold lower than that
of Ab42wt (Fig. 3B). In the Western blot analysis, Ab42wt quickly
aggregated into HMW assemblies after 48 h while Ab42D7H
remained in LMW assemblies until 192 h when it gradually
aggregated into HMW assemblies (Fig. 3D). Using TEM, we
observed more oligomeric or protofibrillar structures in the
Ab42D7H assemblies and more fibrillar structures in the Ab42wt
assemblies after 312 h of incubation (Fig. 4). All of these results
indicate that the D7H mutation results in Ab42 remaining in
LMW assemblies longer and in reduced HMW fibril formation.
Considering that the GdnHCl in our Ab preparation might
affect the assembly state [4], the results of the ThT assay were also
confirmed by preparing Ab in HFIP-DMSO (Fig. S4A, B). In this
condition, the D7H mutation also increased Ab40 fibril formation
and decreased Ab42 fibril formation. Considering the possibility
that artificial assemblies may be induced by PICUP, Western blot
analysis without PICUP was also performed (Fig. S4C, D). These
results also confirmed that the D7H mutation promotes the
formation of Ab40 HMW assemblies and prolongs the time Ab42
remains in LMW assemblies.
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Because the oligomers are generally considered to be the more
neurotoxic Ab assembly state, the increase of Ab42D7H oligomers
may promote neurotoxicity. To determine the effect of the D7H
mutation on the neurotoxicity of Ab42 oligomers, synthetic
Ab42wt and Ab42D7H were prepared using HFIP-DMSO and
incubated at 4uC for 24 h. The neurotoxicity of these Ab42
assemblies on SH-SY5Y human neuroblastoma cells was mea-
sured using the MTT assay. After 48 h of co-incubation with
either 5 mMo r1 0mMA b42D7H, SH-SY5Y cells had significantly
lower survival rates than cells incubated with Ab42wt (Fig. 5). Our
results indicate that the D7H mutation promotes neurotoxicity of
Ab42.
Together, this mutation increased Ab production, Ab42/Ab40
ratio, and prolonged Ab?2 oligomer state with higher neurotox-
icity. Therefore, we propose to classify the D7H mutation as
probable pathogenic according to the algorithm proposed
previously [26].
The D7H mutation alters the biochemical features of ion-
induced Ab assemblies
Histidines at the 6
th,1 3
th and 14
th residues of Ab are important
for the peptide’s interaction with the metal ions, which can also
affect Ab aggregation [19,20]. We speculated that the appearance
of one more histidine at the 7
th residue of AbD7H may enhance
susceptibility to the effect of Zn
2+ or Cu
2+ on Ab aggregation. To
explore this speculation, we incubated Abwt or AbD7H with Zn
2+
or Cu
2+ to observe the kinetics of fibril formation, size distribution,
and morphology of the respective Ab assemblies.
Figure 2. The D7H mutation increases Ab production and the Ab42/40 ratio. (A–C) Western blots were used to monitor the levels of full
length APP, the C99 and C83 fragments (A, C) and the sAPPb fragment (B) in HEK293 cells transfected with empty vector (mock), wt APP or D7H
mutant APP cDNAs. Densitometric analysis on the right showed a significant increase of the C99/C83 ratio and sAPPb in cells expressing D7H mutant
APP in both the absence (A, B) and presence (C) of c-secretase inhibitor L-685,458. (D–F) ELISA showed significantly higher fold-change of Ab40/APP
(D), Ab42/APP (E) and Ab42/40 (F) in the conditioned media of D7H mutant APP transfected cells. All the data were normalized to data from wt APP-
expressing cells (set as 1) in 3 independent experiments (n=3 per experiment) and presented as mean 6 SEM. ***P,0.001, *P,0.05 by one-way
ANOVA and Turkey post-test.
doi:10.1371/journal.pone.0035807.g002
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2+ or Cu
2+ in 1:1,
2:1 and 5:1 (Ab: metal ion) ratios for 80–150 h. We found that
Zn
2+ accelerated while Cu
2+ prolonged initiation of Ab40wt
aggregation as we reported previously [27]. Both ions had stronger
inhibitory effects on fibril formation in Ab40D7H than in Ab40wt in
a dose dependent manner. At a 1:1 ratio with Zn
2+, the ThT
intensity in the saturation phase of Ab40wt was 10% lower than
that of the no ion control while Ab40D7H was 90% lower than that
of the no ion control (Fig. 6A, C). At a 1:1 ratio with Cu
2+, the
ThT intensity of Ab40wt was 50% lower than that of the no ion
control while Ab40D7H was ,100% lower than that of the no ion
control (Fig. 6B, D). These 2 ions also had stronger inhibitory
effects on Ab42 fibril formation for Ab42D7H than for Ab42wt.
Cu
2+ inhibited fibril formation in Ab42D7H to a greater extent
than in Ab42wt, but Zn
2+-induced inhibition was similar for
Ab42wt and Ab42D7H in the ThT assay (Fig. 6E–H).
In the Western blot analysis, Ab was incubated with Zn
2+ or
Cu
2+ at a 1:1 ratio for 144 h. We found that Ab40wt aggregated
into mostly LMW assemblies with or without ions. However, when
Ab40D7H was co-incubated with Zn
2+ or Cu
2+
, we observed fewer
HMW assemblies and more LMW assemblies than in the no ion
control (Fig. 6I). Similar to our findings in figure 3D, both Ab42wt
and Ab42D7H aggregated into HMW assemblies in the no ion
controls after 144 h. When Ab42wt or Ab42D7H was co-incubated
with Zn
2+
, we observed fewer HMW assemblies and more LMW
assemblies than in the no ion control. However, when Ab42D7H,
but not Ab42wt, was co-incubated with Cu
2+
, we observed fewer
HMW assemblies and more LMW assemblies than in the no ion
control (Fig. 6J). The Western blot results are consistent with those
of the ThT assay, indicating that the AbD7H mutation shifts the
sizes distribution of ion-induced Ab oligomers into LMW
assemblies.
For the TEM observations, Ab was incubated with Zn
2+ or
Cu
2+ in a 1:1 ratio for 264–312 h. After incubation with Zn
2+,w e
found that the Abwt assemblies were predominantly annular
protofibrils as we reported previously but the AbD7H assemblies
Figure 3. The D7H mutation promotes Ab40 HMW assemblies and Ab42 LMW assemblies formation. Lyophilized Ab was prepared in
GdnHCl for the ThT assay (A, B) or in HFIP-DMSO for Western blot (C, D), and samples were collected at indicated times. (A, B) The ThT assay was
applied to monitor the kinetics of b-sheet formation for Ab40wt (A,N), Ab40D7H (A,#), Ab42wt (B,N) and Ab42D7H (B,#). Data were averaged from 3–4
independent experiments (n=3 per experiment). (C) Ab40 and (D) Ab42 samples were fixed by PICUP and examined by Western blot to analyze the
size distribution of assemblies during aggregation.
doi:10.1371/journal.pone.0035807.g003
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with Cu
2+, the Abwt assemblies were predominantly protofibrils
and short fibrils. However, the AbD7H assemblies were predom-
inantly amorphous with occasional short fibrils (Fig. 4). The TEM
results indicate that not only the size but also the morphology of
ion-induced Ab oligomers are altered by the D7H mutation.
The D7H mutation promotes the interaction of Zn
2+ and
Cu
2+ with Ab
Our result suggests a higher susceptibility of AbD7H to Zn
2+/
Cu
2+ during aggregation process. To access a more direct evidence
of Ab-ion interaction, we used Bis-ANS [27,28] to probe Ab
conformation at early aggregation stage in the presence or absence
of ions to estimate the binding affinity of Ab-ion complex. The
490 nm fluorescence signals of 50 mMA b in the presence of
varying concentrations of Zn
2+ or Cu
2+ were collected. The final
titration signal of each condition was used as unit for normaliza-
tion (Fig. 7). Fluorescence signals without normalization are shown
in figure S5. The Bis-ANS emission of Ab40wt and Ab40D7H had
,6.5- and ,11.5-fold increase in the presence of Zn
2+ (Fig. S5A,
C) but had ,1.5- and ,2.4-fold decrease in the presence of Cu
2+
(Fig. S5B, D). Thus, at early aggregation stage, the D7H mutation
exaggerated the ion-induced Ab40 structural changes with Zn
2+
increasing but Cu
2+ decreasing exposure of hydrophobic clusters.
For the Zn
2+ titration, saturation of structural changes occurred at
around 200 mMZ n
2+ for Ab40wt (Zn
2+:A b as 4:1) and at around
5 mMZ n
2+ for Ab40D7H (Zn
2+:A b as 1:10, Fig. 7A). For the Cu
2+
titration, saturation of structural changes occurred at around
10 mMC u
2+ for Ab40wt (Cu
2+:A b as 1:5) and at around 5 mM
Cu
2+ for Ab40D7H (Cu
2+:A b as 1:10, Fig. 7B). Our result indicates
Figure 4. Ab morphology in the presence or absence of metal ions was revealed by TEM. Lyophilized Ab was prepared in HFIP-DMSO.
After 264–312 h of incubation in either the presence or absence of Zn
2+ or Cu
2+, the Ab samples were stained by 2% uranyl acetate and monitored by
TEM. In the presence of ions, the AbD7H peptides were predominantly amorphous morphology but not protofibrils as Abwt. Scale bar: 200 nm.
doi:10.1371/journal.pone.0035807.g004
Figure 5. The D7H mutation enhances the neurotoxicity of
Ab42. The neurotoxicities of Ab42wt and Ab42D7H were estimated by
the MTT assay. SH-SY5Y cells were treated with Ab42wt or Ab42D7H at a
final concentration of 0, 5, or 10 mM for 48 h. Cell survival was
determined by normalizing OD570 readings to those of cells not treated
with Ab42 (set as 1) in 3 independent experiments (n=8 per
experiment) and is presented as mean 6 SEM. ***P,0.001, **P,0.01
vs. Ab42wt by ANOVA.
doi:10.1371/journal.pone.0035807.g005
AbD7H Mutation Alters Ion-Induced Aggregates
PLoS ONE | www.plosone.org 6 April 2012 | Volume 7 | Issue 4 | e35807that the D7H mutation promotes Ab40 interaction with Zn
2+ and
Cu
2+, where the Ab interaction with Zn
2+ is especially enhanced
by the mutation.
The D7H mutation has lower redox activity
The redox activity of Ab has been suggested to play a role in
neurotoxicity and oligomerization process. Altered redox activity
may be one of the mechanisms underlying our findings. Thus, we
Figure 6. The D7H mutation shifts Zn
2+ and Cu
2+-induced assemblies toward smaller oligomers with fewer fibrils. (A–H) 25 mMA b was
incubated with 25 mM ThT in Tris buffer containing 0 mM (black), 5 mM (light color), 12.5 mM (medium color) or 25 mM (dark color) of Zn
2+ (red) or
Cu
2+ (blue). (A) Ab40wt + Zn
2+, (B) Ab40wt + Cu
2+, (C) Ab40D7H + Zn
2+, (D) Ab40D7H + Cu
2+, (E) Ab42wt + Zn
2+, (F) Ab42wt + Cu
2+, (G) Ab42D7H + Zn
2+, (H)
Ab42D7H + Cu
2+. (I–J) 25 mMA b40 (I) and Ab42 (J) were co-incubated with 25 mMZ n
2+ or Cu
2+ for 114 h, fixed by PICUP and examined by Western
blot to analyze the size distribution.
doi:10.1371/journal.pone.0035807.g006
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PLoS ONE | www.plosone.org 7 April 2012 | Volume 7 | Issue 4 | e35807examined the redox activity of Ab42wt and Ab42D7H by metal
reduction assay with bicinchoninic acid (Fig. 8) [29]. The reaction
provides a quantitative method for Cu
+ production representing
the capability of Ab to reduce Cu
2+ to Cu
+. Our result
demonstrated that Ab42D7H has ,45% lower Cu
+ production in
comparison to that of Ab42wt. The lower capability of Ab42D7H to
reduce Cu
2+ to Cu
+ suggested a lower redox activity of Ab42D7H
than Ab42wt.
Discussion
In this study, we report a novel intra-Ab mutation, AbD7H,
which has a ‘‘double punch’’ effect on the disease progress of AD
by modulating both Abproduction and oligomer formation.
APP overexpressing cell culture study indicated that the D7H
mutation enhances the amyloidogenic cleavage pathway and raises
Ab production and the Ab42/40 ratio. In vitro examination
indicated that the D7H mutation shifts Ab40 aggregation into the
fibril-prone pathway and Ab42 aggregation into the oligomer-
prone pathway. According to the algorithm proposed by
Guerreiro to classify AD mutations, we consider that this D7H
mutation could be classified as ‘‘probably pathogenic’’ [26].
In addition, we characterized the biochemical features of
AbD7H-ion complex, including the kinetic of fibril formation, size
distribution, morphology and binding affinity. Our results of Abwt-
ion are all compatible with others [27,30,31,32]. Therefore, we
provide an index of the biochemical features of Ab-ion complex
with a genetic hint, which might be more relevant to AD
pathogenesis. Our study may contribute to the knowledge of
designing Ab-ion interrupting therapy in AD.
The effect of intra-Ab mutations on APP processing
Shifting APP processing into amyloidgenic pathway is one of the
key factors in AD pathogenesis [24]. We speculated that the
increase in Ab levels and Ab42/40 ratio of D7H mutant APP may
accelerate Ab accumulation in the brain. Usually, intra-Ab
mutations are less prone to interfere with APP processing. Only
the A2V, E11K, and A21G mutations enhance amyloidogenic
cleavage [8,33,34]. Interestingly, the D7N Tottori mutation does
not affect Ab levels or the Ab42/40 ratio in the conditioned media
of stably transfected N2a cells [14]. Besides the b-site cleavage to
generate the C99 fragment, b-secretase could also cleave APP at
the b9-site between Tyr10 and Glu11 to generate an 89 amino
acid fragment (C89). The E11K mutation blocks the b9-site and
shifts cleavage of APP to the b-site, causing increased Ab
production [8]. In this study, we did not detect significant
differences in C89 level between wt APP and D7H mutant APP
expressing cells, indicating that the D7H mutation does not
interfere with b9 cleavage of APP.
Moreover, APP processing and trafficking could be regulated by
imbalance of copper or zinc [35,36,37,38]. Zn
2+ and Cu
2+ also
bind to the E1 and E2 domain at N-terminal APP. Metal binding
to E1 domain is related to the iron transport and APP ferroxidase-
like activity [39]. Metal binding to E2 domain is suggested to relate
with APP processing [40]. However, whether D7H changes metal
binding to APP and alters APP structure, function and processing
Figure 7. The D7H mutation promotes the binding of Zn
2+ and Cu
2+ to Ab. The structural changes of 50 mMA b40wt (&)o rA b40D7H (%)
during 0 to 20 mMZ n
2+ (A) and Cu
2+ (B) titration were monitored by 5 mM Bis-ANS. (A inlet) Ab40wt (&) and Ab40D7H (%) were titrated by 0 to
200 mMZ n
2+. The signals at 490 nm of Bis-ANS fluorescence were normalized and plotted to ion concentration. Data were presented as mean 6 SEM
from 3 independent experiments.
doi:10.1371/journal.pone.0035807.g007
Figure 8. The D7H mutation decreases the redox activity of
Ab42 in metal reduction assay. Reduction of Cu
2+ to Cu
+ was
performed by BCA assay. Freshly prepared 10 mMA b42wt and Ab42D7H
were mixed with BCA solution containing 4% CuSO4 to perform the
redox activity assay. Data were presented as mean 6 SEM (n=3),
***P,0.0001.
doi:10.1371/journal.pone.0035807.g008
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favors the amyloidogenic cleavage pathway needs further inves-
tigation.
The role of the Ab N-terminal region in aggregation and
toxicity
Similar to most of the intra-Ab mutants, the Ab42D7H mutant
induced more cell death than Ab42wt, suggesting that the D7H
mutation-induced aggregates are neurotoxic. The D7H mutation
may increase toxicity through its effects on the duration of Ab
oligomer formation or on the structures of the aggregates thus
formed. However, the SH-SY5Y cell might not be a good model of
neurotoxic effect of Ab as Ab42wt showing only a trend of toxicity
(Fig. 5). For future studies, the pathological role of AbD7H should
be confirmed in primary culture, brain slices, or D7H mutant APP
transgenic mice.
To our surprise, the D7H mutation had distinct effects on Ab40
and Ab42 fibrillization, which has not been reported for other
intra-Ab mutations. The fibrogenic properties of Ab42 are signed
by two additional residues, Ile41 and Ala42, altering its structure
and hydrophobicity [41]. Nevertheless, an additional secondary
structure between the Phe4-His14 region is found in Ab40 but not
Ab42 fibrils [42]. The D7H mutation, which is located in this
region, may have distinct effects on the aggregation properties of
Ab40 and Ab42 by altering this N-terminal structure. This AbD7H
mutant provides an interesting tool for further biochemical study
of the effect of the N-terminal region on the differential
aggregation properties of Ab40 and Ab42.
Effect of metal ions on Ab aggregation
The high concentration of Zn
2+ or Cu
2+ in glutamatergic
synapses has been proposed to promote Ab aggregation and
toxicity [21]. Interrupting Ab-ion interaction with a metal-protein-
attenuating compound, PBT2, has beneficial effects in the AD
mouse model and in the phase II clinical trial [22]. We speculate
that the pathogenicity of AbD7H might be partially contributed by
its higher affinity toward Zn
2+/Cu
2+ (Fig. 7). Consistent with this
speculation, we show that the D7H mutation exaggerated the
Zn
2+/Cu
2+-induced Ab conformational changes (Fig. S5). The
opposite effect of Zn
2+ and Cu
2+ on Ab conformation at early
aggregation stage has also been shown in our previous study [27].
Cu
2+ has been shown to inhibit Ab fibrillization and to induce
assemblies with multiple morphologies [27,43,44]. The altered
properties of AbD7H-Cu
2+ complex might be the result of Cu
2+
interaction with the additional histidines at Ab position 7. Most of
the free Cu
2+ interacting with His6/His13 or His6/His14
promotes b-sheet-rich fibril formation, while a small proportion
of Cu
2+ interacting with the adjacent imidazole rings at His13/
His14 inhibits fibril but promotes ‘‘amorphous’’ structure forma-
tion [44,45]. Therefore, we speculate that the additional two
adjacent imidazole rings at His6/His7 of AbD7H promote the
formation of ‘‘amorphous’’ non-b-sheet assemblies.
Zn
2+ has been shown to inhibit fibril but to promote annular
protofibril formation of Abwt [27,46]. In this study, Zn
2+ promoted
‘‘amorphous’’ assemblies formation of AbD7H. Computational
studies revealed that Asp7 is important for the stabilization of
Zn
2+-induced oligomers [47]. Therefore, we speculate that the loss
of Asp7 in AbD7H destabilize Zn
2+-induced annular protofibril and
thus promote ‘‘amorphous’’ aggregate formation. Together, our
findings suggest that the ‘‘amorphous’’ aggregates induced by
Zn
2+/Cu
2+ might be more relevant to AD pathology.
Mutations in 21
st–23
rd residues of Ab showed no differences in
ion-induced aggregation while the ion-induced aggregation of Ab
N-terminus mutations has not been examined [48]. Our results
provide the first genetic indication linking Zn
2+ and Cu
2+-induced
Ab aggregation to the pathogenesis of AD.
Redox activity of Ab
The histidine residues on Ab are thought to play a role in
controlling the redox activity of Cu
2+ [49]. In our study, although
AbD7H had higher Cu
2+ binding affinity (Fig. 7), AbD7H had lower
capability to reduce Cu
2+ to Cu
+ (Fig. 8). This indicates that the
redox activity of Ab-Cu
2+ might be controlled by multiple factors
rather than be simply controlled by the Cu
2+ binding affinity.
Redox activity has been suggested to involve in the Ab-induced
cytotoxicity and oligomerization [18,50]. Lower redox activity of
Ab42D7H suggested that redox activity is not the primary factor for
Ab42D7H-induced cytotoxicity. Furthermore, Ab-Cu
+ complex is
suggested to promote cross-linking of peptides through dityrosine
formation to stabilize oligomers [51,52]. Nevertheless, Ab42D7H
had lower Cu
+ production (Fig. 8) but retained aggregates in
LMW oligomers (Fig. 6), indicating that the Ab42D7H LMW
oligomers might not be stabilized by dityrosine formation or redox
activity. Together, the change in redox activity might not be the
mechanism underlying our findings, but more details of redox
activity other than copper reduction should be addressed.
Methods
Human subject and cell line information
This study was approved by Institutional Review Board at
Taipei Veterans General Hospital. The written informed consent
was obtained from the patient. The patient’s guardian also
consented on the behalf her because her capacity to consent was
reduced. Human embryonic kidney (HEK293) cells were from
Bioresource Collection and Research Center (60019, Hsinchu,
Taiwan). SH-SY5Y human neuroblastoma cells were from Sigma-
Aldrich (94030304, MO, USA).
Materials
Metal ions were all prepared in double-distilled Mill-Q water.
Purchasing information for all the materials used in this study is
listed in supplementary materials (Method S1).
Plasmid construction
cDNA encoding human wild-type hAPP770 was subcloned into
a CMV promoter/enhancer-driven expression vector (pDEST26).
A QuickChange II site-directed mutagenesis kit was used to
introduce the D7H mutation into the wt APP construct. The
correctness of the resulting constructs was confirmed by sequence
analysis.
Cell culture
Human embryonic kidney (HEK293) cells were transfected with
the wt APP and the D7H mutant APP plasmids by Lipofectamin
2000 according to the manufacturer’s protocol. 36 hours after
transfection, cells were lysed with Trizol reagent to isolate total
protein following the manufacturer’s instruction.
APP and Ab measurement
To determine the levels of full length APP and the C-terminal
fragments, 70 mg (Fig. 2A) and 30 mg (Fig. 2C) of cell lysates were
separated by 15% Tris-Tricine SDS-PAGE and analyzed with a
mouse anti-APP N-terminus antibody (22C11) or rabbit anti-APP
C-terminus antibody (AB5352). To measure sAPPb, conditioned
media of APP expression cells were separated by 8% Tris-glycine
SDS-PAGE and analyzed with a rabbit anti-sAPPb antibody
AbD7H Mutation Alters Ion-Induced Aggregates
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were separated by 4%, 10%, and 15% stacking Tris-Tricine SDS-
PAGE, and analyzed with an anti-Ab 17–24 antibody (4G8).
Human Ab levels in APP transfected cells were quantitated by
enzyme-linked immunosorbent assay (ELISA) using high sensitiv-
ity human b Amyloid 40 and 42 kits that use anti-Human Ab 11–
28 as the capture antibody. All antibodies used in this study do not
recognize Ab-Asp7 as an epitope.
Ab preparation
Ab peptides were synthesized using Fmoc (N-(9-fluorenyl)
methoxycarbonyl) chemistry and purified by reverse-phase high-
performance liquid chromatography [53]. The molecular mass
was identified by matrix-assisted laser desorption/ionization-time
of flight (MALDI-TOF) mass spectrometry (UltraFlex II). For the
Western blot, transmission electron microscopy (TEM) and 3-(4,5-
Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)
assays, Ab was prepared with hexafluoroisopropanol (HFIP) and
dimethyl sulfoxide (DMSO) and incubated at room temperature
for the indicated times [54]. For the thioflavin T (ThT) assay, Ab
were prepared with guanidine hydrochloride (GdnHCl) and
incubated at 25uC for the indicated times [27,54]. For the
GdnHCl preps, lyophilized Ab was dissolved in 8 M GdnHCl,
incubated for 15–20 mins, and added to 10 mM Tris-HCl,
pH 7.4 (GdnHCl: Tris buffer, 1:9 v/v) for refolding. Impurities
or aggregates were removed by centrifugation at 17,0006g for
20 min at 4uC. The supernatant was collected, and the Ab
concentration was determined by the absorbance at 280 nm
(e=1,280 cm
21M
21) [55]. For the HFIP-DMSO preps, lyophi-
lized Ab was dissolved in HFIP and incubated for 1 h at room
temperature. HFIP was removed by vacuum overnight. HFIP-
treated Ab films were dissolved in DMSO (Ab: DMSO, 1:100 w/
v) and added to 10 mM Tris-HCl, pH 7.4 (DMSO: Tris, 1:9 v/v).
After centrifugation at 17,0006ga t4 uC for 20 min, the
supernatant was collected and quantified by absorbance at
280 nm.
Photo-induced cross-linking of unmodified proteins
(PICUP)
The experiment was performed as described previously [25,27].
Briefly, 9 volumes of Ab solution were mixed with 0.5 volume each
of 1 mM Tris (2,29-bipyridyl) dichlororuthenium(II) (RuBpy) and
20 mM ammonium persulfate. After mixing, the samples were
exposed to a blue light LED in a closed chamber with a manual
switch for 10 sec. The cross-linking reaction was stopped by
adding SDS-PAGE sample buffer, and the samples were subjected
to Tris-Tricine SDS-PAGE.
ThT assay
25 mMo fA b was incubated in 25 mM ThT at 25uCi na n
ELISA plate and monitored with a microplate reader. The ThT
emission was measured at 485 nm, while excitation was at
442 nm. The signals were collected automatically every hour for
100 h.
MTT assay
SH-SY5Y human neuroblastoma cells with ,75% confluence
were treated with Abwt or AbD7H for 48 hours at 37uC. After
48 hours of incubation, the MTT was added, and the cultures
were incubated for an additional 3 h. Cells were lysed overnight
using a lysis buffer containing 10% SDS and 20 mM HCl. The
absorbance was measured at a wavelength of 570 nm by an
ELISA reader.
Transmission electron microscopy (TEM)
10 mlo f2 5mMA b samples was placed on glow-discharged,
400-mesh formvar carbon-coated copper grids, negatively stained
with 2% uranyl acetate, and examined with a TEM with an
accelerating voltage of 75 kV.
Ion titration and Bis-ANS fluorescence
Fluorescence emission spectra of 4,4-Bis (1-anilinonaphthalene
8-sulfonate) (Bis-ANS) were collected at wavelengths ranging from
450 to 550 nm with an excitation wavelength of 400 nm. 50 mM
Ab in 5 mM Bis-ANS was titrated with 520 mM ZnCl2 or CuCl2 to
final ion concentrations in the range of 0–20 mM and with
6640 mM ZnCl2 to final ion concentrations in the range of 20–
200 mMa t2 5 uC in a circulating water bath. The total volume was
increased by less than 10% after titration. The signals at 490 nm
were used for normalization. The changes of each titration signal
to the initial titration signal were normalized to the change of the
final titration signal to the initial titration signal. The normalized
data were plotted against metal ion concentration.
Metal reduction assay
Ab42wt and Ab42D7H were prepared in the HFIP-DMSO
preps. The metal reduction assay was performed as described
previously [29] by using bicinchoninic acid (BCA) assay kit. The
working solutions were freshly prepared following the manufac-
turer’s manual. Briefly, the working solution, 200 ml, was added to
polystyrene 96-well plate with transparent bottom and 25 mlo f
Ab42wt and Ab42D7H with final concentrations at 10 mM were
added into the wells. The plate was then incubated at 37uC and
read continuously at absorbance of 562 nm by SpectraMax M5
Multi-Mode microplate reader to monitor Cu
+ production. The
absorption was generated from the BCA-Cu
+ complex. The
saturated absorption at 120 min were obtained, subtracted by the
buffer control, averaged (n=3), and normalize to the intensity
obtained from Ab42wt.
Supporting Information
Figure S1 Pedigree and laboratory data. (A) The pedigree of a
Taiwanese family with early onset of AD. The index patient is
indicated by an *. The family members with AD are labeled in
black. (B) The early-onset AD patient showed normal laboratory
data in complete blood count, liver function, thyroid function,
renal function and syphilis. This excluded other possibilities from
neurodegenerative diseases.
(TIF)
Figure S2 Transfect efficiency and APP maturity of wt APP and
D7H mutant APP. HEK293 cells were transfected with 0.8 mg
pDEST26 plasmid encoding either wt APP or D7H mutant APP.
(A) After 24 h, number of cells transfected with APP was analyzed
by a mouse anti-APP N-terminus antibody (22C11, red) and
number of cell were estimated by DAPI staining (blue).
Transfection efficiencies for both plasmids were ,20%. Scale
bar: 50 mm. (B) After 36 h, 30 mg of cell lysates were separated by
8% SDS-PAGEs. APP was analyzed with a mouse anti-APP N-
terminus antibody (22C11) and actin was served as loading
control. APP expression level was similar in wt APP and D7H
mutant APP expressing cells. (C) APPs were separated by 8%
SDS-PAGEs and analyzed by anti-APP N-terminus antibody
(22C11). Graph showing the fold change of the ratio of mature/
immature APP indicates that the ratio of APP maturity of wt APP
and D7H mutant APP is similar. Data from wt APP expressing
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mean 6 SEM.
(TIF)
Figure S3 The D7H mutation did not alter intracellular Ab
level. ELISA showed no significant increase in ratios of Ab40/
APP, Ab42/APP and Ab42/40 in the cell lysate of wt APP and
D7H mutant APP transfected cells. Data from wt APP expressing
cells were set as 1 in 3 independent experiments and presented as
mean 6 SEM.
(TIF)
Figure S4 Different Ab preparations also confirmed that the
D7H mutation promotes Ab40 HMW assemblies but promotes
Ab42 LMW assemblies formation. (A, B) Lyophilized Ab40 (A)
and Ab42 (B) were prepared in HFIP-DMSO for the ThT assay.
Data were averaged from 3–4 independent experiments. (C, D)
Lyophilized Ab40 (C) and Ab42 (D) were prepared in HFIP-
DMSO for Western blotting without PICUP treatment.
(TIF)
Figure S5 The representative emission spectra of Ab40wt (A, B)
or Ab40D7H (C, D) in the presence of 0, 10, 20, and 50 mMZ n
2+
(A, C) or Cu
2+ (B, D) are shown.
(TIF)
Method S1 Human embryonic kidney (HEK293) cells were
from Bioresource Collection and Research Center (60019,
Hsinchu, Taiwan). SH-SY5Y human neuroblastoma cells were
from Sigma-Aldrich (94030304, MO, USA). MALDI-TOF mass
spectrometry was produced by Bruker BioSciences (Bruker
Daltonics Ultraflex, MA, USA). The microplate reader for the
ThT assay and the BCA assay was produced by Molecule Devices
(SpectraMax M5, CA, USA). TEM was produced by Hitachi (H-
7000, Tokyo, Japan). Fluorescence microscope was produced by
ZEISS (Axio Observer A1, Ireland). Spectrofluorometer for
binding affinity was produced by Horiba Jobin Yvon (Fluoro-
Max-3, USA). Copper grids for TEM were purchased from EMS
Inc. (18086, PA, USA). Lipofectamin 2000 and pDEST26 were
from Invitrogen (11809-019 and 11668-500, USA). The site-
directed mutagenesis kit was from Stratagene (200521, CA, USA).
Antibody 22C11, AB5352 and 4G8 were from Millipore
(MAB348, AB5352 and MAB1561, MA, USA). Antibody for
sAPPb was from Convance (9138-005). Antibody for b-actin was
from GeneTex (GTX110564, CA, USA). Mounting medium with
DAPI was from by Vector Laboratoies (H-1200, CA, USA).
ELISA kits for human Ab40 and Ab42 were purchased from
Wako (294-62501 and 290-62601, Japan). GdnHCl was from
Merck (1.04220.1000, Darmstadt, Germany). ThT, Trizol,
1,1,1,3,3,3-Hexafluoro-2-propanol (HFIP), c-secretase inhibitor
(L-685,458), Tris (2,29-bipyridyl) dichlororuthenium (II) (Ru(Bpy)),
CuCl2 and ZnCl2 were purchased from Sigma-Aldrich (T3516,
T9424, 105228, SI-L1790, 224758, 12317 and 31650, MO, USA).
Tris and ammonium persulfate (APS) were from Amresco (0826
and 0486, OH, USA). 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenylte-
trazolium bromide (MTT) was from Bio Basic Inc. (298-93-1,
Taipei, Taiwan). ELISA reader was produced by SUNRISE,
TECAN (Switzerland). The bicinchoninic acid (BCA) assay kit was
from Thermo Scientific (Waltham, MA, United States). The
polystyrene 96-well plate used for BCA assay was from UltraViolet
(Taipei, Taiwan).
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